Erowid References Database
Harris, D, Baggott, M, Jones, RT, Mendelson, J.
“MDMA Pharmacokinetics and Physiological and Subjective Effects in Humans”.
Problems in Drug Dependence: Proceedings of 61st Annual Meeting of the College of Problems of Drug Dependence. 2000;ed. Harris, Washingt.
The purpose of this study is to describe the pharmacokinetics of
3,4-methylenedioxymethamphetamine (MDMA) and its physiological and subjective effects. Eight volunteers experienced with the use of MDMA each received either a placebo, low-dose (0.5 mg/kg) MDMA, or moderate dose (1.5 mg/kg) MDMA, in a double blind crossover study. The moderate dose (but not the low dose) MDMA produced statistically significant increases in systolic and diastolic blood pressure, heart rate, and rate-pressure product when compared to the placebo condition, comparable to those produced by stimulants. Mean
peak increases for heart rate, systolic and diastolic were 26 BPM, 20 mmHg, and 13 mmHg, respectively, for the moderate dose. Peak physiological values for the moderate dose occurred 1 hr (heart rate) to 2.5 hr (diastolic blood pressure) after dosing. The moderate dose MDMA produced a number of significant subjective effects, including those associated with the use of stimulants and those associated with the use of LSD. Our moderate dose was thought to be comparable to that typically used by most of our participants and produced peak subjective effects at 2 hr after dosing. In this condition,
global intoxication rating rose from 0 to a peak value of 52 on a 100 point rating scale. Pharmacokinetics and cortisol response will be described.
[ Cite HTML